Dose-response screening of NSCLC cell lines was used to find cells that were naturally resistant to gefitinib and osimertinib, evaluating both short-term viability and long-term clonogenic activity to explore the mechanisms underlying resistance to EGFR-TKI therapy in NSCLC (Fig. 1A and S1A-C). This evidence concerns the gene EGFR and non-small cell lung carcinoma.